Assess whether RWE can replace or only supplement an RCT (b1d9b2)

Situation

Regulatory-affairs lead in a safety team sitting on a new disproportionate signal has one working extract — scientific-advice briefing book — after a site-change that invalidates stability claims. Regulatory-affairs lead in a safety team sitting on a new disproportionate signal has scientific-advice briefing book after a site-change that invalidates stability claims. If that extract cannot support RWE can replace or, the honest Pharma & Life Sciences CMC and Development Pathways output is hold.

Decision

Regulatory-affairs lead in a safety team sitting on a new disproportionate signal must choose RWE can replace / Only supplement an RCT using scientific-advice briefing book after a site-change that invalidates stability claims.

Hypotheses to test

• Authorize RWE can replace now; scientific-advice briefing book already has the discriminator after a site-change that invalidates stability claims.
• Keep Only supplement an RCT in force until scientific-advice briefing book is completed after a site-change that invalidates stability claims for regulatory-affairs lead.
• Treat scientific-advice briefing book as RWE can replace because both readings appear after a site-change that invalidates stability claims.
• Refuse a Pharma & Life Sciences close: regulatory-affairs lead does not have the page RWE can replace or turns on in scientific-advice briefing book.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• Check whether scientific-advice briefing book supports the labeled claim regulatory-affairs lead would keep.
• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• For this Pharma & Life Sciences CMC and Development Pathways file, read scientific-advice briefing book against a site-change that invalidates stability claims and write the one fact that would move RWE can replace or for regulatory-affairs lead.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / CMC and Development Pathways packet (scientific-advice briefing book after a site-change that invalidates stability claims). The follow-on CMC and Development Pathways action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.